Francine Foss, MD, and Matthew Lunning, DO, FACP, detail current treatment approaches for peripheral T-cell lymphoma.
Back
Updates and Research Trends in Peripheral T-Cell Lymphoma From ASH 2025
Francine Foss, MD, and Matthew Lunning, DO, FACP, provide an in-depth review of the current and evolving treatment landscape for peripheral T-cell lymphoma (PTCL), drawing on data presented at the 2025 ASH Annual Meeting.
Updates and Research Trends in Peripheral T-Cell Lymphoma From ASH 2025
Episodes
All
All
Francine Foss, MD, and Matthew Lunning, DO, FACP, discuss varying treatment approaches for peripheral T-cell lymphoma in newly diagnosed vs relapsed disease.
Francine Foss, MD, and Matthew Lunning, DO, FACP, highlight key findings from the PRIMO trial evaluating duvelisib in relapsed/refractory peripheral T-cell lymphoma.
Francine Foss, MD, and Matthew Lunning, DO, FACP, look ahead to the phase 3 TERZO trial of duvelisib in nodal TFH peripheral T-cell lymphoma.
Francine Foss, MD, and Matthew Lunning, DO, FACP, discuss findings for duvelisib plus chidamide and CHOP in newly diagnosed angioimmunoblastic T-cell lymphoma.
Francine Foss, MD, and Matthew Lunning, DO, FACP, discuss other key data from ASH 2025 and ongoing research to watch in peripheral T-cell lymphoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to BH-30643 in EGFR C797S+ NSCLC
2
FDA Grants Fast Track Designation to Sapanisertib and Serabelisib Plus Paclitaxel in Advanced Endometrial Cancer
3
FDA Grants Fast Track Designation to ETX-19477 in BRCA-Mutated HR+/HER2– Breast Cancer
4
Dr Leary on a Neo-Epitope-Based Vaccine With or Without Pembrolizumab in Platinum-Sensitive Recurrent Ovarian Cancer
5